摘要
目的:研究125I标记抗胃癌单克隆抗体MAb3H11自胃癌周围粘膜下注射后的药代动力学过程,以及患者血清人抗鼠抗体(HAMA)水平的动态变化。方法:拟行放射免疫导向手术的胃癌患者10例,经胃镜直视于癌周围胃粘膜下注射125I标记的MAb3H11(抗体剂量0.2～0.5mg/例),定时采取血样和尿样、手术中留取部分肿瘤标本,测定放射性强度;患者在抗体皮试前和注射标记抗体后每周留取血样,分离血清,ELISA法检测血清HAMA。结果:经计算机模拟,胃癌周围粘膜下注射标记抗体125I-MAb3H11后,其血浆分布、清除符合二房室模型,T1/2α:2.21±1.40小时,T1/2β:43.63±7.27小时;每克肿瘤组织对标记抗体摄取量可达注射剂量的(0.215±0.117)%;注射标记抗体对患者无明显不良影响,MAb3H11皮试前及胃粘膜下注射标记抗体后动态观测至第4～6周,未发现血清HAMA滴度明显升高。结论:125I标记抗胃癌单克隆抗体MAb3H11自癌灶周围胃粘膜下注射的方法,适用于胃癌放射免疫导向手术。
Objective:To investigate the pharmacokinetics and the human anti-murine im munoglobulin antibody(HAMA)responses in gastric cancer patients undergoing radioimmunogu-id ed surgery(RIGS)using 125 I labeled anti-gastric cancer monoclonal antibody(Mab)3H11.Methods:Ten operable patients with gastric cancer were injected with 125 I labeled Mab3H11submucosally via endoscopy.The dose of Mab3H11ranged from0.2mg to0.5mg .After injection,the blood and urine samples were acquired in regular times and tumor specimens were ob tained in operations.All samples were tested for radioactivity.Before skin test to murine Mab3H11and after injection of labeled antibody,the blood samples were obtained weekly,after serum was isolated,the HAMA was assayed by ELISA.Results:The plasma distribution and clearance of 125 I labeled Mab3H11best fitted by a two-compartment model with a distribution half-life(T1/2α)of2.21±1.40h and an eliminationhalf-life(T1/2β)of43.63±7.27h.The mean antibody uptake by primary tumors was(0.215±0.117)%of injected dose per gram.No complication was found in these pateints.All ten patients were negative for HAMA before skin test,and no patient devel-oped a positive HAMA level in a period of4to6weeks after admin istration of ra dio labeled MAb3H11.Conclusion:Submucosal administration of 125 I labeled Mab3H11is suit able for ra-dioimmunoguided surgery in gastric cancer treatment.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2002年第3期153-156,共4页
Chinese Journal of Clinical Oncology
基金
国家"九五"攻关项目基金资助(编号:96-906-01-16)
